It has been established that tau-related pathology and the burden of NFTs correlates much better with cognitive dysfunction, compared to the amyloid beta burden (Nelson et al., 2012; Malpas et al., 2020); hence this AD pathology may represent a more important target to achieve successful clinical translatability. This evidence concerns the gene MAPT and Alzheimer disease.